3 Biotech Stocks Most Wall Street Analysts Are Bullish About
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
0
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2199022/abbvie-abbv-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2199022
Dec 15, 2023 - In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.
0
Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago
https://www.zacks.com/stock/news/2197856/here-s-how-much-you-d-have-if-you-invested-1000-in-abbvie-a-decade-ago?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2197856
Dec 14, 2023 - Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
0
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
https://www.fool.com/investing/2023/12/12/abbvie-just-followed-pfizers-big-move-heres-what/?source=iedfolrf0000001
Dec 12, 2023 - It's making a major acquisition to beef up a key area of its pipeline.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Top Stock Reports for AbbVie, NIKE & BHP
https://www.zacks.com/commentary/2194633/top-stock-reports-for-abbvie-nike-bhp?cid=CS-ZC-FT-research_daily-2194633
Dec 07, 2023 - Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).
0
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
https://www.zacks.com/stock/news/2194306/immunogen-imgn-gets-fda-priority-review-for-elahere-sbla?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194306
Dec 06, 2023 - The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0